Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.385 – $0.408
Volume7,674
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.96M
Price / earnings
—
Price / book
0.45×
Price / sales
—
EV / sales
—
EV / EBITDA
2.86×
Profitability
Earnings per share
-$0.47
Return on assets
-24.03%
Return on equity
-53.58%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.85×
Quick ratio
1.85×
Cash ratio
1.8×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.57M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MBIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$850K
$946K
$880K
$987K
$957K
$787K
$1.22M
-$223K
Research and development
$208K
$224K
$178K
-$317K
-$333K
$98K
-$964K
$197K
Total operating expenses
$1.06M
$1.17M
$1.06M
$670K
$624K
$885K
$253K
$1.02M
Operating income
-$1.06M
-$1.17M
-$1.06M
-$670K
-$624K
-$885K
-$253K
-$1.02M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$964K
-$1.07M
-$955K
-$538K
-$468K
-$762K
-$153K
-$952K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$964K
-$1.07M
-$955K
-$538K
-$468K
-$762K
-$153K
-$952K
Net income attributable to common shareholders
-$964K
-$1.07M
-$955K
-$538K
-$468K
-$762K
-$153K
-$952K
EBITDA
-$1.06M
-$1.17M
-$1.06M
-$670K
-$624K
-$885K
-$219K
$77K
Basic earnings per share
-$0.14
-$0.16
-$0.14
-$0.08
-$0.07
-$0.19
-$0.05
-$0.90
Diluted earnings per share
-$0.14
-$0.16
-$0.14
-$0.08
-$0.07
-$0.19
-$0.05
-$0.90
Recent news
Company coverage with links to the original publishers.
The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.
Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.
Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.
Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock, Series C-1 warrants, and Series C-2 warrants, raising approximately $8 million in gross proceeds.
Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.